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Adverse Effects of Antimicrobials via Predictable or Idiosyncratic
Inhibition of Host Mitochondrial Components
Alison E. Barnhill, Matt T. Brewer, and Steve A. Carlson
Department of Biomedical Sciences, Iowa State University College of Veterinary Medicine, Ames, Iowa, USA
This minireview explores mitochondria as a site for antibiotic-host interactions that lead to pathophysiologic responses mani-
fested as nonantibacterial side effects. Mitochondrion-based side effects are possibly related to the notion that these organelles
are archaic bacterial ancestors or commandeered remnants that have co-evolved in eukaryotic cells; thus, this minireview fo-
cuses onmitochondrial damage that may be analogous to the antibacterial effects of the drugs. Special attention is devoted to
aminoglycosides, chloramphenicol, and fluoroquinolones and their respective single side effects related to mitochondrial distur-
bances. Linezolid/oxazolidinone multisystemic toxicity is also discussed. Aminoglycosides and oxazolidinones are inhibitors of
bacterial ribosomes, and some of their side effects appear to be based on direct inhibition of mitochondrial ribosomes. Chloram-
phenicol and fluoroquinolones target bacterial ribosomes and gyrases/topoisomerases, respectively, both of which are present in
mitochondria. However, the side effects of chloramphenicol and the fluoroquinolones appear to be based on idiosyncratic dam-
age to host mitochondria. Nonetheless, it appears that mitochondrion-associated side effects are a potential aspect of antibiotics
whose targets are shared by prokaryotes andmitochondria—an important consideration for future drug design.
SIDE EFFECTS OF ANTIBACTERIAL DRUGS
The desired activity of an antibiotic is to kill or prevent thegrowth of offending pathogenic bacteria, and yet these drugs
may impact the host in an injurious manner. Generalized adverse
events are common to most antibiotics (e.g., gastrointestinal dis-
tress with any oral antibacterial drug), but certain antibiotics are
associated with specific effects (Table 1). Some adverse events are
mild, e.g., yellowing of the teeth for tetracyclines (77, 79), in-
creased intestinal peristalsis related to erythromycin therapy (7,
67), and reversible orange discoloration of skin and body fluids as
observed with rifampin treatment (23, 31). Altered drug metabo-
lism (106) is a common side effect that, in the absence of co-drug
therapy, could also be considered mild. More serious side effects
include photosensitivity (44) and anaphylactoid reactions (34)
observed with many agents, ototoxicity (27, 83) following amino-
glycoside therapy, chondrotoxicity (85, 88) and retinopathy (95)
with fluoroquinolones, neuropathies associated with metronida-
zole (30, 107) and linezolid (15), and lactic acidosis and serotonin
syndrome attributed to linezolid (21, 61).Other consequences can
be severe or even devastating such as: the dermonecrolytic Ste-
vens-Johnson syndrome associated with sulfonamide antimicro-
bial agents (74, 81); nephrotoxicity related to aminoglycosides
(63, 73); aplastic anemia due to chloramphenicol (9, 91); hepatitis
caused bymany drugs, including isoniazid (72, 89); neuromuscu-
lar blockade related to aminoglycoside (64, 65) or lincosamide (4,
70) therapy; myopathies due to ionophores (5, 28, 75); and neo-
plasia related to metronidazole (19). All of these side effects are
likely to have unique etiologies given the diverse array of events,
the unrelated pharmacodynamic properties of certain antimicro-
bial classes, and the unique chemical nature of these agents. How-
ever, as new evidence is unveiled, mitochondrial alterations form
the basis for a divergent array of adverse effects observed in asso-
ciation with chemically distinct drugs. Mitochondrial compo-
nents (e.g., ribosomes, gyrases, and topoisomerases) share little
homology with prokaryotic cohorts and thus are less likely to be
inhibited by antibiotics than are prokaryotic ribosomes, gyrases,
and topoisomerases (36, 47, 96, 97). However, it appears that
some inhibitors of prokaryotic ribosomes, gyrases, and topoisom-
erases can elicit unexpected effects on mitochondria that lead to
side effects of these antibiotics. Inhibition of protein synthesis, the
major impetus for the antibacterial effects of rRNA inhibitors (6,
58), appears to be relevant to many of the mitochondrion-based
toxicities.
AMINOGLYCOSIDES AND OTOTOXICITY
Aminoglycosides are irreversible inhibitors of the 30S, and less
commonly the 50s, bacterial ribosomal subunit, thereby serving as
inhibitors of protein synthesis. Most aminoglycosides are bacteri-
cidal, which is likely related to toxic peptides synthesized by the
30S subunit after the aminoglycoside-ribosome interaction. The
nature of this interaction is potentially related to the electrochem-
ical polarity of these drugs. Aminoglycosides are so polar that oral
bioavailability is very poor, resulting in limited drug passage
through lipidmembranes in the gut. This polarity may contribute
to a covalent interaction with the 30S subunit.
There has long been an association between aminoglycosides
(streptomycin, kanamycin, neomycin, gentamicin, tobramycin,
and amikacin) and ototoxic side effects in 20% of human patients
receiving any of these drugs (17, 83). The main site of action for
the aminoglycoside ototoxicity is either the cochlea or the vestibu-
lum (62), resulting in hearing loss or dysequilibrium, respectively.
There is an increase in toxicity whenmore than one ototoxic drug
is used in combination with another. Premature infants and chil-
dren may be more susceptible to ototoxicity as the inner ear de-
velops (35). In human patients on gentamicin, those with the
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A1555GorC1494T (less frequent)mutation in the 12S rRNAgene
of the mitochondria tend to be more susceptible to ototoxicity,
indicating a link to mitochondrial aberration (35). The secondary
structure of the A site of the 30S bacterial ribosome is very similar
to the secondary structure of the A site encompassing the human
mitochondrialmutation (40). These researchers propose amolec-
ular mechanism whereby the A1555G or C1494T mutation leads
to mitochondrial 12S ribosomal secondary structures that mimic
the analogous structure in the 30S bacterial ribosome. While it
appears that aminoglycosides can bind to the mitochondrial 12S
ribosome, it remains unclear how this interaction leads to selective
dysfunction of cochlear or vestibular cells.
CHLORAMPHENICOL AND APLASTIC ANEMIA
Chloramphenicol limits bacterial growth by binding to the 50S
ribosomal subunit and inhibiting protein synthesis in pro-
karyotes. Unfortunately, ribosomal similarities between bacteria
and mitochondria (26) may provide the basis for mitochondrial
sensitivity to chloramphenicol-mediated inhibition of protein
synthesis.Mitochondrial DNA codes for 13 polypeptides involved
inmetabolic activities, and none of these genes are expressed from
the nucleus (2, 3). Expression of the transferritin receptor seems to
be the most relevant to the chloramphenicol-mitochondrion in-
teraction. Specifically, chloramphenicol diminishes mitochondri-
on-based transferritin receptor expression, resulting in ferritin de-
pletion in mitochondria. The resulting imbalance between
organic and inorganic iron coincides with an excess of nonferritin
iron in the mitochondria of patients receiving chloramphenicol
(50).
Aplastic anemia has been associated with chloramphenicol
therapy formany years (10, 41), and this finding is the basis for the
ban on chloramphenicol use in food-producing animals (100).
Chloramphenicol-mediated hematotoxicity manifests as either a
reversible (41), predictable, dose-dependent, early-onset, mild
anemia characterized by reticulocytopenia with occasional leuko-
penia and thrombocytopenia observed during therapy (80, 92,
104) or a posttreatment pancytopenia that is unpredictable, irre-
versible, dose independent, and occasionally fatal (103, 104). The
early-onset myelosuppression primarily affects erythropoiesis,
whereby the bone marrow exhibits an essentially normal land-
scape of cell types with reduced numbers of maturing erythroid
cells (8, 76). The latent aplastic anemia manifests as a severe pan-
cytopenia related to an absence of myeloid constituents in the
marrow (32, 99, 102).
The lipoidal nature of chloramphenicol results in a large vol-
ume of distribution that includes many “privileged” sites such as
the brain and the bonemarrow (42). Chloramphenicol can readily
cross most cell membranes, and yet the side effects are presented
in the marrow. Maturing hematopoietic cells are completely de-
pendent upon transferritin for iron intake (68), and these cells are
exquisitely sensitive to hypoferritinization. Consequently, ferri-
tin-free mitochondria are metabolically dysfunctional, and af-
fected erythrocytes manifest this phenomenon via hypochromic-
microcytic anemia during the dose-dependent anemia associated
TABLE 1 Summary of side effects attributed to specific antibiotics or classes of antibioticsa
Antibiotic or antibiotic class Adverse effect Basis of the adverse effect Reference(s)
Aminoglycosides Nephrotoxicity Permeabilization of cells in renal proximal tubular cells 38, 94, 108
Aminoglycosides Neuromuscular blockade Acetylcholine receptor antagonism 48, 53
Aminoglycosides Ototoxicity Inhibition of the 12S ribosomal subunit in mitochondria in cochlear and
vestibular cells
35, 40
Chloramphenicol Aplastic anemia Inhibition of mitochondrial protein synthesis, resulting in decreased
expression of the transferritin receptor
39, 50, 56, 59
Erythromycin (and possibly other
macrolides)
Intestinal hyperperistalsis Activation of the motilin receptor that promotes intestinal kinetics 14
Fluoroquinolones Dysglycemia Reduced GLUT1 gene expression 1, 22
Fluoroquinolones Orthopedic anomalies Inhibition of DNA gyrase and topoisomerase in mitochondria in
chondrocytes, osteoblasts, and tenocytes
11, 13, 51,
69, 84, 101
Fluoroquinolones Retinopathies Fluoroquinolones absorbing UV light and creating radicals resulting in
damage to lens proteins; histological changes in the outer nuclear
layer as well as the photoreceptor inner and outer segments
16, 105
Ionophores Myopathies Ion channel dysregulation in myocytes 5, 37, 75
Isoniazid Hepatitis Generation of an electrophilic metabolic that precipitates proteins in
hepatocytes
57






Inhibition of mitochondrial protein synthesis 21, 55, 60,
61, 87
Serotonin syndrome Monoamine oxidase inhibition for the serotonin syndrome
Metronidazole (nitroimidazole) Reversible neuropathy Dentate nucleus anomalies 30, 98
Metronidazole Neoplasia DNA damage 19
Rifampin and other antibiotics Orange/red discoloration of
skin and body fluids
Unclear, although it may be related to bilirubinemia 31
Sulfonamides Stevens-Johnson syndrome Immune mediated 20, 43
Tetracyclines (not doxycycline) Yellowing of the teeth Chelation of dental calcium 77, 79
Tetracyclines Vestibular problems Otic osmotic changes 45
a For each side effect, the mechanistic basis is listed. Alterations in drug metabolism and gastrointestinal effects are not included due to the large numbers of these events. Those
involving mitochondrial damage are shaded. Ribosomal inhibitors that do not damage mitochondria are italicized.
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with chloramphenicol. Aplastic anemia appears to have ancillary
factors such as underlying mitochondrial dysfunction (50), ge-
netic polymorphisms that accentuate chloramphenicol binding to
mitochondrial rRNA (39, 56), or a genetic predisposition that
enhances the ability of the bone marrow to nitroreduce chloram-
phenicol into its myelotoxic derivative (59). That is, chloram-
phenicol-mediated aplastic anemia is related to mitochondrion-
based alterations in ferritin but the exaggerated nature of this
adverse event does not have a clearly defined basis and thus remains
idiosyncratic. A nitro group, present in chloramphenicol but absent
in the less toxic derivatives florfenicol and thiamphenicol, appears to
be the chemical determinant of the aplastic anemia (86). Of all the
mitochondrion-based side effects mentioned in this minireview,
chloramphenicol-associatedaplastic anemia is theonly example con-
fined to a single antibiotic within an antibiotic class. Mitochondrial
disturbances have been noted for multiple drugs within the fluoro-
quinolone, aminoglycoside, and oxazolidinone classes.
FLUOROQUINOLONES AND CHONDROTOXICITY
A putative side effect of fluoroquinolones is chondrotenotoxicity
(29) that can lead to arthropathies (93) and ruptured tendons
(82). These particular side effects are mostly observed in juvenile
patients (49) inwhom tendons and joints are rapidly proliferating.
However, this is not a clearly established phenomenon (18) but is
worthy of inclusion in this review.
Fluoroquinolones are inhibitors of bacterial gyrases and topo-
isomerases. These drugs stabilize enzyme/cleaved DNA com-
plexes within the cell, thus terminating DNA replication, whereby
fluoroquinolone-exposed bacteria are not viable and are not able
to recover once the drug is gone (54). DNA degradation has been
reported in mitochondria exposed to fluoroquinolones (46), but
there is no direct evidence of a link between this event and the
inhibition of mitochondrial gyrases or topoisomerases. It is pos-
sible that this phenomenon is due to fluoroquinolone inhibition
of mitochondrial enzymes, but mitochondrial topoisomerases
bear less than 30% homology to their prokaryotic counterparts,
and previous studies demonstrated thatmitochondrial topoisom-
erases are not inhibited by nalidixic acid (47) or ciprofloxacin
(71).
In vitro toxicity has been demonstrated in tenocytes and chon-
drocytes (11, 84, 101), and the chondrotoxicity has been associ-
ated with reactive oxygen species (51). Osteoblasts are also sensi-
tive to fluoroquinolones, since these cells produce excess lactate in
the presence of therapeutically relevant concentrations of the drug
(13).Noother specific cell types have been shown to be sensitive to
fluoroquinolones; thus, it remains unclear why these drugs have a
tropism for mitochondria in tenocytes, chondrocytes, and osteo-
blasts. Fluoroquinolone side effects are usually observed in juve-
nile patients, and thus, their developing cells may contain mito-
chondria that are hypersensitive to this antibiotic class (69).
However, the lack of hematopoietic anomalies suggests that other
factors dictate fluoroquinolone damage to tenocytes, chondro-
cytes, and osteoblasts.
Hyaluronic acid, which is essential for the maintenance of sy-
novial joints, has recently been shown to have a protective effect
for radical-induced mitochondrial DNA damage (25). In this sce-
nario, hyaluronic acid may be utilized by mitochondria damaged
by fluoroquinolone exposure, thereby creating a shortage of hyal-
uronic acid at the articular surface of the joint. Thiswould account
for the degradation of articular cartilage (78) observed in fluoro-
quinolone-associated arthropathies, but it would not account for
the ruptured tendons, for which tenocyte-specific damage is the
putative etiology.
The chondrotoxic effects of fluoroquinolonesmay not be com-
pletely due to mitochondrial disturbances. For example, there is
growing evidence that these drugs sequester magnesium ions es-
sential for integrins responsible for cell-cell adhesion (84). This
has been further substantiated by the work of Pfister et al., who
demonstrated that administration of magnesium and vitamin E
has a protective effect for fluoroquinolone-induced chondrotox-
icity in a rat model (66). Thus, fluoroquinolone-mediated chon-
drotoxicity probably relates to the cumulative effects of mito-
chondrial DNA damage, sequestration of essential cofactors, and
an imbalance of chondroprotective substances. In summary, these
side effects of fluoroquinolones are idiosyncratic, but mitochon-
drial damage is likely at the core of these toxicities.
MULTISYSTEMIC TOXICITY OF LINEZOLID AND OTHER
OXAZOLIDINONES
Linezolid is a member of the oxazolidinone group of antimicro-
bials that inhibits bacterial ribosomes by binding to the 23S ribo-
some and preventing the 30S-50S fusion (52). Disruption of
mammalian mitochondrial protein synthesis has been implicated
in three side effects of linezolid—hyperlactatemia,myelosuppres-
sion, and neuropathies.
Garrabou et al. demonstrated that linezolid-mediated hyper-
lactatemia is due to the blockade of cytochrome c oxidase synthe-
sis in mitochondria (21). This enzyme is the final step in the elec-
tron transport chain, and its inhibition halts a key ATP synthetic
step in this pathway. This leads to a compensatory excess of gly-
colysis-derived pyruvate that is anaerobically converted to lactate,
hence the hyperlactatemia. This same phenomenon was observed
with eperezolid (60).
Nagiec et al. (60) also demonstrated that mammalian cell pro-
liferation is hampered in the presence of eperezolid. This finding is
consistent with the myelosuppressive effects of oxazolidinones
whereby myeloprogenitor cell maturation is hampered (24, 90).
Eperezolid has no effect on cell proliferation in rhoO cells lacking
mitochondrial DNA, whereas the mitochondrial DNA-bearing
parental cells (143B) were inhibited by eperezolid (60).
Linezolid-associated optic neuropathies have been reported on
numerous occasions in patients receiving the drug beyond the
standard 28-day regimen (reviewed in reference 33). Clinical fea-
tures of these optic neuropathies are diagnostically consistentwith
those observed in other optic neuropathies definitively associated
with mitochondrial dysfunction. A genetic predisposition seems
likely since linezolid-associated optic neuropathies have been ob-
served only in a few patients on extended-term therapy with lin-
ezolid (33). Peripheral neuropathies appear to have the same
mechanistic basis as the optic neuropathies, and extended lin-
ezolid therapy underlies this condition as well (12).
In summary, oxazolidinone-mediated hyperlactatemia ap-
pears to be related to the inhibition of mitochondrial protein syn-
thesis. Since these antibiotics are protein synthesis inhibitors in
bacteria, the evidence suggests that this side effect is more predict-
able than idiosyncratic.
CONCLUSIONS
In summary, aminoglycosides, chloramphenicol, fluoroquinolo-
nes, and linezolid have side effects associated with mitochondrial
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damage in the host. Except for neuropathies associated with lin-
ezolid, these side effects occur at doses approved for the intended
clinical applications. That is, the therapeutic index (toxic dose in
50%of patients [TD50]/effective dose in 50%of patients [ED50]) is
essentially unity for the majority of these mitochondrion-based
side effects. Aminoglycoside-associated ototoxicity and linezolid-
mediated hyperlactatemia do not appear to be idiosyncratic, i.e.,
the other side effects are based uponmitochondrial alterations but
the associated changesmay be “off-target” effects uponmitochon-
drial components unrelated to the prokaryotic component tar-
geted by the antibiotic.
Chloramphenicol inhibitsmitochondrial synthesis of a protein
necessary for iron transport, aminoglycosides inhibit the 12S ri-
bosomal subunit in vestibular and cochlear cells, fluoroquinolo-
nes cause DNA damage in mitochondria associated with joints
and tendons, and linezolid inhibits cytochrome oxidase c synthe-
sis inmitochondria. Three of these four drugs are antibacterial via
direct prokaryotic ribosome inhibition, but a number of other
ribosomal inhibitors (e.g., tetracyclines, macrolides, strepto-
gramins, and pleuromutilins) do not appear to have side effects
associated with mitochondrial damage. Additionally, aminogly-
cosides, chloramphenicol, fluoroquinolone, and linezolid have
side effects that are not associated with mitochondrial damage—
neuromuscular blockade associated with aminoglycosides, chlor-
amphenicol-mediated alterations in drug metabolism, retinopa-
thies subsequent to fluoroquinolone therapy, and serotonin
syndrome associated with linezolid. While some of the toxicities
described here are idiosyncratic, the design of new antibiotics
should, nonetheless, account for potential commonalities in bac-
terial and mitochondria whereby preference is given to drugs that
target prokaryotic pathways that are truly extant inmitochondria.
Cell membrane synthesis inhibitors and inhibitors of metabolic
cascades are examples of antibiotics that appear to have advan-
tages in terms of minimizing untoward effects in patients.
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